Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal Hemodynamic Responses to Aliskiren in T2DM
NCT00660309Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2008
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aliskiren in hypertension (HTN) (2 arms), sponsored by Novartis. Primary endpoints: Change From Baseline in Renal Plasma Flow After a Single Dose at Day 2, Change From Baseline to Steady State Trough in Renal Plasma Flow at Day 15 and 2 more. Started Apr 2008; status: completed.
02
Drugs
aliskiren
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00660309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00660309.